Author

D. S. Peeper

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Assay:proteomics· 2 Approach:statistical model· 2

Frequent Co-Authors

D. W. Vredevoogd· 3 shared M. Altelaar· 3 shared B. de Bruijn· 2 shared J. Boshuizen· 2 shared M. A. Ligtenberg· 2 shared N. L. Visser· 2 shared O. Krijgsman· 2 shared A. Atmopawiro· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. W. Vredevoogd

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Phosphoprotein dynamics of interacting tumor and T cells by HySic

S. Ibanez-Molero, J. Pruijs, A. Atmopawiro, F. Wang, M. Altelaar, D. S. Peeper, K. E. Stecker

This paper introduces HySic, a method to quantify protein and phosphorylation dynamics between interacting tumor and T cells, revealing the RHO/RAC/PAK1 pathway's activation and its role in T cell-mediated tumor killing.

bioRxiv · Jun 5, 2023 · PreprintCancer Biology

TSC2 regulates tumor susceptibility to TRAIL-mediated T cell killing by orchestrating mTOR signaling

D. S. Peeper, C.-P. Lin, J. J. H. Traets, D. W. Vredevoogd, N. L. Visser

This study shows TSC2 regulates tumor susceptibility to TRAIL-mediated T cell killing by modulating mTOR signaling and TRAIL receptor expression.

bioRxiv · May 9, 2022Cancer Biology

PREDICTIVE IMMUNE CHECKPOINT BLOCKADE CLASSIFIERS DISTINGUISHING MONO- VERSUS COMBINATION THERAPY REQUIREMENT

O. Krijgsman, K. Kemper, J. Boshuizen, D. W. Vredevoogd, E. A. Rozeman, S. Ibanez Molero, B. de Bruijn, P. Cornelissen-Steijger, A. Shahrabi, M. Del Castillo Velasco-Herrera, J.-Y. Song, M. A. Ligtenberg, R. J. C. Kluin, T. Kuilman, P. Ross-MacDonald, , D. S. Peeper

This paper develops two genetic signatures, InTumor and ExTumor, to predict immune checkpoint blockade response in melanoma patients, enabling stratification for monotherapy or combination therapy.

bioRxiv · Jul 14, 2020 · PreprintCancer Biology

LOSS OF UBIQUITIN LIGASE STUB1 AMPLIFIES IFNγ-R1/JAK1 SIGNALING AND SENSITIZES TUMORS TO IFNγ

G. Apriamashvili, D. W. Vredevoogd, O. Krijgsman, O. B. Bleijerveld, M. A. Ligtenberg, B. de Bruijn, J. Boshuizen, D. D'Empaire Altimari, N. L. Visser, J. D. Londino, M. Altelaar, D. S. Peeper

This study shows that loss of STUB1 enhances IFNγ signaling and sensitizes tumors to IFNγ, suggesting STUB1 inhibition combined with PD-1 blockade could improve cancer immunotherapy.

bioRxiv · Jul 7, 2020 · PreprintCancer Biology

Combined EGFR and ROCK inhibition in TNBC leads to cell death via impaired autophagic flux

S. Rontogianni, S. Iskit, S. van Doorn, D. S. Peeper, M. Altelaar

This study shows that combined EGFR and ROCK inhibition in TNBC causes cell death by blocking autophagic flux, leading to autophagic vacuole accumulation.

bioRxiv · Jun 5, 2019Cancer Biology